Assenagon Asset Management S.A. Makes New Investment in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Assenagon Asset Management purchased 280,649 Dianthus Therapeutics shares worth approximately $27.4 million, giving it a 0.51% stake. Institutional investors and hedge funds collectively own 47.53% of DNTH.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $124.27; HC Wainwright raised its target to $158 while maintaining a Buy rating.
• Dianthus remains a loss-making clinical-stage biotech: it reported a quarterly loss of $0.90 per share versus the expected $0.85 loss, despite revenue exceeding estimates. Insiders have also sold 253,779 shares worth about $25.9 million over the past 90 days.

Assenagon Asset Management S.A. bought a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 280,649 shares of the company's stock, valued at approximately $27,358,000. Assenagon Asset Management S.A. owned 0.51% of Dianthus Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Seven Fleet Capital Management LP increased its holdings in Dianthus Therapeutics by 451.6% in the 1st quarter. Seven Fleet Capital Management LP now owns 80,809 shares of the company's stock valued at $6,781,000 after buying an additional 66,158 shares during the period. DV Trading LLC acquired a new stake in Dianthus Therapeutics in the first quarter valued at about $2,228,000. Glenmede Trust Co. NA grew its position in Dianthus Therapeutics by 96.5% in the first quarter. Glenmede Trust Co. NA now owns 12,470 shares of the company's stock valued at $1,046,000 after acquiring an additional 6,125 shares during the last quarter. Stempoint Capital LP grew its position in Dianthus Therapeutics by 7.8% in the first quarter. Stempoint Capital LP now owns 85,502 shares of the company's stock valued at $7,175,000 after acquiring an additional 6,218 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in Dianthus Therapeutics by 96.4% during the first quarter. Janus Henderson Group PLC now owns 16,500 shares of the company's stock worth $1,384,000 after acquiring an additional 8,100 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 31,249 shares of the business's stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the sale, the executive vice president directly owned 31,249 shares of the company's stock, valued at $3,157,086.47. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Adam M. Veness sold 30,000 shares of Dianthus Therapeutics stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the transaction, the senior vice president owned 30,000 shares of the company's stock, valued at $2,424,000. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 253,779 shares of company stock valued at $25,931,495. Insiders own 3.02% of the company's stock.

Dianthus Therapeutics News Roundup

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target for Dianthus Therapeutics to $158 from $130 and maintained a “Buy” rating. The target implies additional upside and reflects the firm’s long-term expectations for the company’s complement-therapy pipeline. Dianthus Therapeutics Price Target Raised to $158
• Positive Sentiment: HC Wainwright improved several near- and long-term earnings forecasts, including narrowing its estimated 2026 loss to $3.87 per share from $4.81 and projecting a return to profitability by 2030 at $10.75 per share. The firm continues to rate DNTH “Buy” with a $158 target. HC Wainwright Dianthus Therapeutics estimates
• Positive Sentiment: Institutional interest has expanded, led by BlackRock’s approximately $402 million new position. Institutional investors now own about 47.5% of the stock, which may reinforce investor confidence and liquidity. Dianthus Therapeutics institutional ownership and insider trading
• Neutral Sentiment: Analyst views are generally favorable but not unanimous. DNTH has a “Moderate Buy” consensus, with 12 Buy ratings and one Sell rating; the average price target is $124.27, below HC Wainwright’s $158 objective. Analysts conflicted on Dianthus Therapeutics
• Negative Sentiment: CEO Marino Garcia sold 166,000 shares for approximately $17.9 million, reducing his direct holdings by 71.8%. Although the sale may be part of personal financial planning, its size can weigh on sentiment, particularly after the stock’s strong advance. Dianthus Therapeutics CEO stock sale
• Negative Sentiment: The company remains loss-making and recently missed quarterly EPS expectations, reporting a $0.90 loss per share versus an expected $0.85 loss. Revenue exceeded estimates, but the result highlights continued execution and funding risks for this clinical-stage biotech.

Analysts Set New Price Targets

DNTH has been the subject of a number of research analyst reports. Raymond James Financial reiterated a "strong-buy" rating and set a $131.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday. HC Wainwright increased their target price on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a "buy" rating in a research report on Thursday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Guggenheim reiterated a "buy" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Wolfe Research reiterated an "outperform" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $124.27.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock opened at $108.92 on Monday. The business has a 50-day simple moving average of $94.72 and a 200 day simple moving average of $80.90. Dianthus Therapeutics, Inc. has a one year low of $18.08 and a one year high of $114.55. The firm has a market capitalization of $5.95 billion, a price-to-earnings ratio of -26.25 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. On average, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source